1. Home
  2. RAND vs DARE Comparison

RAND vs DARE Comparison

Compare RAND & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$10.20

Market Cap

30.3M

Sector

Finance

ML Signal

HOLD

Logo Dare Bioscience Inc.

DARE

Dare Bioscience Inc.

HOLD

Current Price

$2.06

Market Cap

33.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
DARE
Founded
1969
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.3M
33.4M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
RAND
DARE
Price
$10.20
$2.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
897.0
138.0K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
10.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,807,885.00
Revenue This Year
N/A
$2,115.12
Revenue Next Year
N/A
$122.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.00
$1.27
52 Week High
$20.00
$9.19

Technical Indicators

Market Signals
Indicator
RAND
DARE
Relative Strength Index (RSI) 47.64 45.12
Support Level $10.03 $1.95
Resistance Level $10.49 $2.24
Average True Range (ATR) 0.09 0.11
MACD 0.01 0.01
Stochastic Oscillator 60.43 22.00

Price Performance

Historical Comparison
RAND
DARE

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About DARE Dare Bioscience Inc.

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Share on Social Networks: